Risankizumab (Skyrizi)
Author: Blake Mumford

Introduction

  • 75mg/0.83mL prefilled syring

Dosing

  • 150mg at week 0 and week 4, then every 12 weeks

PBS quantity

  • Initial: 2 * 75mg, 2 repeats (7 months supply)
  • Continuing:: 2 * 75mg, 1 repeat (6 months supply)

Mechanism of action

  • Antibody directed against p19 subunit of IL-23 and IL-39

Indications

  • Moderate - severe chronic plaque psoriasis
  • Psoriatic arthritis